Pairing GLP-1 drugs with other treatment could help people with psoriasis, The Hill reports. Tap through for the research behind it.
Recap by typeshit. Full story at The Hill.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
US Anti-Doping's Dr Matt Fedoruk gives athletes a short rundown on peptides, covering what is prohibited in sport and what is allowed.
The Hill looks at how pairing a GLP-1 drug with other treatment could bring added benefits for people living with psoriasis.
Loading…